StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Down 10.1 %
EVOK opened at $0.47 on Thursday. The firm has a market cap of $4.06 million, a P/E ratio of -0.26 and a beta of 0.36. Evoke Pharma has a 52 week low of $0.40 and a 52 week high of $1.77. The business’s fifty day simple moving average is $0.48 and its 200 day simple moving average is $0.70.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The business had revenue of $1.74 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 6/10 – 6/14
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- What is a Dividend King?
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
